Test New Editor

Dr Lee Fook Kay heads Temasek Foundation’s Pandemic X Office that develops and executes philanthropic outreach and projects for preparedness and countermeasures for future pandemics. His office supports regional networking of scientific communities and health policy makers, and capacity building through science and technology sharing. It also catalyses efforts for biobanking to promote data and material sharing in scientific networks and surveillance of emerging infections and neglected tropical diseases with pandemic potential.

Dr Lee was Chief Scientist of Ministry of Home Affairs before he retired from civil service and joined Temasek Foundation. He was instrumental in building national S&T capabilities in chemical, biological, radiological, and nuclear defence for national security during his career with the Ministries of Defence and Home Affairs. He graduated with PhD in Chemistry from National University of Singapore in 1990 and was designated as Chartered Chemist in 1994 by UK Royal Society of Chemistry.

Mr Colin Lim is the Chief Information Officer and Chief Data Officer at Singapore’s Ministry of Health.

His previous role was the Chief Executive Officer of mobilityX, a mobility as a service startup, that was backed by SMRT and Toyota Tsusho. Prior to that, Colin was Managing Director SMRT Services and Vice President, Strategic Relations Office SMRT. He earlier worked at IBM UK, where his last role was Geography Leader, Intelligent Transport Systems, then a new IBM business initiative for which he identified and developed new markets and opportunities for IBM globally.

Colin also served in the Singapore Administrative Service where his last appointment was Senior Director of the Planning and Organisation Division in the Ministry of Home Affairs. Prior to that, he was the Registrar of Vehicles and Group Director for Vehicle and Transit Licensing at the Land Transport Authority. He has also worked at the Ministries of Manpower and Transport.

Colin holds a Master of Business Administration from the University of Oxford and a Bachelor of Science (Economics) (Honours) from the London School of Economics on a Public Service Commission scholarship. 

Adj Asst Prof Chua Chi Siong is Medical Director (MD), Regional Health System Office (RHSO), National University Health System (NUHS). He provides clinical leadership and oversight for health-related interactions with residents in consultation with community partners and ensure the quality of care and clinical services provided by RHSO. He also provides strategic inputs to the development and implementation of NUHS population health strategy.

Adj Asst Prof Chua was Medical Director, Jurong Community Hospital (JCH) from 2011-2022, where he oversees the planning, opening and ramp up of JCH. He continues to be the Head, Clinical Quality as well as the senior consultant, Post-Acute and Continuing Care Department in JC

Prof Lee is the Deputy Group CEO (Regional Health System), SingHealth where he leads population health efforts; and chairs the Planning Committee for the upcoming Eastern General and Community Hospitals.

Prof Lee is an Adjunct Professor at the Saw Swee Hock School of Public Health, NUS; Duke-NUS Medical School and SUTD.   He had served on international committees under WHO, IHF and JCI.

Mr Edwin Chew is currently the Chief Digital Strategy Officer for the Agency for Integrated Care (AIC). He leads a team to support the Singapore community care sector digitalization uplifting journey. He also manages the IT needs of AIC which supports the long-term care sector.

Prior to AIC, Edwin was the Program Director at the Integrated Health Information Systems Pte Ltd, a wholly owned subsidiary of MOH Holdings. In his role as the Program Director, he managed a team of healthcare IT professionals to support the 3 Singapore Public Healthcare Clusters. He program-managed and developed IT systems for use in the public healthcare domain areas such as electronic medical records, pharmacy closed-loop medication, laboratory, radiology and specialties including ICU, ENT, Ophthalmology, dental clinics, operating theatres. He is also involved in enabling the IT capabilities for the new healthcare buildings. Separately, Edwin also took on the role as the CIO for Woodlands Health Campus (2014 to 2017) and IT Director Tan Tock Seng Hospital (2009 to 2011).

With a career of over 20 years of IT experience in banking and healthcare industry, Edwin has implemented many large-scale banking and healthcare projects.

Edwin graduated with a Bachelor of Science (Computing) from Swinburne University of Technology, Australia and he holds a Master of Business Administration from University of Adelaide, Australia. He is also a Certified IT Project Manager (Senior) by the Singapore Computer Society (SCS).

As the Chief Executive Officer for Synapxe, Ms Ngiam Siew Ying plays a key role in the master-planning and development of Health technology to advance healthcare transformation, and improve population health amidst a dynamic and complex health eco-system.

Siew Ying entered Public Service in 1999. Prior to her appointment in Synapxe, she was Deputy Secretary (Policy) in the Ministry of Health where she led the development of systems planning, finance and corporate policies.

Through her career, Siew Ying has held various appointments in the National Population and Talent Division under the Prime Minister’s Office, Ministry of Transport, Ministry of Defence, and the Defence Science and Technology Agency.

Submit your application for Healthcare InnoMatch 2024 on the Challenge Portal by 8 April 2024, 12:00 SGT. Results will be announced by 12 May 2024. Multi-participation is welcomed. Fill in the application form available in the participant space, providing the following:

• Applicant and Company Information

• Solution Pitch Deck (7 slides)
  

Pitch Deck Guidelines can be downloaded in the Challenge Portal.

Shortlisted start-ups and SMEs are to submit your full proposal, addressing the following but not limited to:

• Healthcare (organisational) needs and relevance

• Innovation (competitive advantage, current competing strategies, technologies, competitors)

• Maturity/ market readiness

• Impact (quantifiable)

• Ease of transition to adopt by users

• Business plan (i.e. commercial applications, economic viability, go-to-market strategy of solution)

• Clinical, technical and operational readiness

• IT viability

• Prior or existing trials, proof-of-concept, proof-of-value and/or clinical validation results

• Safety and regulatory registrations/ certifications/ licenses
  

Results will be announced by 14 Jul 2024. Up to twenty (20) start-ups and SMEs will be selected to move to the next shortlisting round.

Up to twenty (20) start-ups and SMEs will be invited to present your solution at Engagement Sessions with our clinical partners and reviewers.

Engagement Sessions will be held virtually at night, between 1800 and 2100 SGT (GMT+8/ UTC+8). Each session will be approximately fifteen (15) to twenty (20) minutes, with time allocated for the presentation and Q&A. More details on the arrangement of schedule will be shared nearer to date.

Results will be announced by 18 Aug 2024. Up to nine (9) finalists will be selected.

Finalists will be coached by experts in preparation for the Finale Event. This may include coaching on refining the value proposition of the solution, budgeting, business plan, pitching. Oral presentation of your solutions is required during the coaching sessions. Guidance on submission materials for the Finale Event will be provided nearer to date.

Finalists will pitch to the Judging Panel composed of senior management from the partner healthcare clusters and domain experts. Finalists in Singapore are required to attend the event in-person, while finalists overseas may dial-in through the online live-streamed platform.

Up to three (3) winners will be selected at the end of the Challenge, announced on the day of the event itself.

Successful winning start-ups and SMEs will be matched to one of the participating healthcare clusters to carry out test-bedding.

Winners will be granted three (3) months of preparation time to finalise the project agreement (and additional three (3) months if ethics approval is required); up to six (6) months to complete test-bedding; and up to two (2) months to complete the evaluation.

Test-Bedding Phase (Oct 2024 – Mar 2026)

• Refine the test-bed protocol and define success criteria of the test-bed with your partner healthcare cluster. You would also define the pricing for subsequent purchase, subject to the solution meeting pre-agreed success criteria. You may be required by your partner hospital to supplement more documentation to facilitate the test-bedding and potential adoption.

• A Project Agreement should be set up within three (3) months (an additional three (3) months may be granted if ethics approval is required).

• Test-bedding should start no later than Apr 2024. Complete test-bedding in a simulated and/or clinical environment complying to regulations and institutional policies with your partner healthcare cluster. Test-beds should be completed within twelve (12) months.

Evaluation Phase (Apr 2026 – May 2026)

• Upon completion of the test-bedding phase, the partner healthcare clusters would evaluate the success of the test-bed.

• All CHISEL 2024 test-bed solutions are to be evaluated using the CHI Evaluation Framework (CHIEF). CHIEF is a holistic framework for the evaluation of innovative solutions seeking real world deployment. Evaluation costs should be included in your application.
  

  You may also engage additional services (e.g. statistical analysis, study design, sample calculation etc.) from CHIEF or an independent expert for the purposes of the test-bed at your discretion.